We have received a $50K grant from the Barth Syndrome Foundation, “Development of Mitochondria-Targeted Peptide Compounds as Barth Syndrome Therapeutics. This work will explore a library of compound variants optimized as therapeutics for treating dysfunctional lipid biogenesis of Barth Syndrome patients.

---